Forest and Caraco settle Lexapro litigation in the US
This article was originally published in Scrip
Executive Summary
Forest Laboratories and Lundbeck have settled US patent infringement litigation with Detroit-based Caraco Pharmaceutical on their blockbuster antidepressant, Lexapro (escitalopram oxalate). The deal paves the way for Caraco to sell a generic version once other companies have begun to do so. Any launch may be delayed, however, as the first of Forest's three Orange Book-listed patents, covering the escitalopram compound, expires in March 2012.